利拉鲁肽治疗2型糖尿病合并非酒精性脂肪性肝病的研究进展

谢海平; 林帆; 陈彦; 郑铭

doi:10.3969/j.issn.1001-5256.2020.09.046

利拉鲁肽治疗2型糖尿病合并非酒精性脂肪性肝病的研究进展

DOI: 10.3969/j.issn.1001-5256.2020.09.046

1. 福建医科大学省立临床医学院
2. 福建省立医院老年科
3. 福建省立金山医院(福建省立医院南院)内科
4. 福建省立医院干部特诊科

基金项目:

北京医卫健康公益基金会(B183027)；

详细信息

中图分类号: R575.5;R587.2
计量
- 文章访问数: 702
- HTML全文浏览量: 28
- PDF下载量: 112
- 被引次数: 0
出版历程
- 出版日期: 2020-09-20

Advances in liraglutide in the treatment of type 2 diabetes with nonalcoholic fatty liver disease

Provincial Clinical Medical College, Fujian Medical University

Research funding:

摘要

摘要:
非酒精性脂肪性肝病(NAFLD)是常见的慢性肝脏疾病,患病率逐年上升,胰岛素抵抗及氧化应激是主要发病机制,目前仍缺乏有效的治疗药物。胰岛素抵抗也是引起2型糖尿病的主要发病机制,糖尿病患者NAFLD患病率较非糖尿病患者高。利拉鲁肽是人胰高血糖素样肽1受体激动剂,可改善胰岛素抵抗,越来越多研究发现利拉鲁肽对2型糖尿病合并NAFLD有一定疗效,相关机制仍未完全明确。就利拉鲁肽治疗2型糖尿病合并NAFLD的疗效及相关机制的研究进展进行综述。
- 非酒精性脂肪性肝病 /
- 糖尿病,2型 /
- 利拉鲁肽
Abstract:
Nonalcoholic fatty liver disease( NAFLD) is a common chronic liver disease,and its prevalence rate is increasing year by year.Insulin resistance and oxidative stress are the main pathogeneses of NAFLD,and there are still no effective drugs for the treatment of this disease. Insulin resistance is also a main pathogenesis of type 2 diabetes,and people with type 2 diabetes have a higher prevalence rate of NAFLD than those without diabetes. Liraglutide is a human glucagon-like peptide-1 analogue and can improve insulin resistance,and more and more studies have found that liraglutide has a certain therapeutic effect in patients with type 2 diabetes and NAFLD,while related mechanisms have not been fully clarified. This article reviews the therapeutic effect and related mechanisms of liraglutide in the treatment of type 2 diabetes and NAFLD.
- non-alcoholic fatty liver disease /
- diabetes mellitus,type 2 /
- liraglutide

HTML全文

参考文献(42)

[1] YOUNOSSI ZM,KOENIG AB,ABDELATIF D,et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes[J]. Hepatology,2016,64(1):73-84.

[2] Chinese Society of Endocrinology,Chinese Medical Association. Consensus for diagnosis and treatment of nonalcoholic fatty liver diseases and metabolic disorders(2nd Edition)[J].J Clin Hepatol,2018,34(10):2103-2108.(in Chinese)中华医学会内分泌学分会．非酒精性脂肪性肝病与代谢相关紊乱诊疗共识(第二版)[J]．临床肝胆病杂志，2018,34(10):2103-2108.

[3] BARB D,PORTILLO-SANCHEZ P,CUSI K. Pharmacological management of nonalcoholic fatty liver disease[J]. Metabolism,2016,65(8):1183-1195.

[4] YOUNOSSI ZM,GOLABI P,DE AVILA L,et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes:A systematic review and meta-analysis[J]. J Hepatol,2019,71(4):793-801.

[5] EGUCHI Y,KITAJIMA Y,HYOGO H,et al. Pilot study of liraglutide effects in non-alcoholic steatohepatitis and non-alcoholic fatty liver disease with glucose intolerance in Japanese patients(LEAN-J)[J]. Hepatol Res,2015,45(3):269-278.

[6] PETIT JM,CERCUEIL JP,LOFFROY R,et al. Effect of liraglutide therapy on liver fat content in patients with inadequately controlled type 2 diabetes:The lira-NAFLD study[J]. J Clin Endocrinol Metab,2017,102(2):407-415.

[7] RIZVI AA,PATTI AM,GIGLIO RV,et al. Liraglutide improves carotid intima-media thickness in patients with type 2 diabetes and non-alcoholic fatty liver disease:An 8-month prospective pilot study[J]. Expert Opin Biol Ther,2015,15(10):1391-1397.

[8] ARMSTRONG MJ,HOULIHAN DD,ROWE IA,et al. Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes:Individual patient data meta-analysis of the LEAD program[J]. Aliment Pharmacol Ther,2013,37(2):234-242.

[9] FENG WH,BI Y,LI P,et al. Effects of liraglutide,metformin and gliclazide on body composition in patients with both type 2diabetes and non-alcoholic fatty liver disease:A randomized trial[J]. J Diabetes Investig,2019,10(2):399-407.

[10] MANTOVANI A,BYRNE CD,SCORLETTI E,et al. Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes:An updated systematic review of randomized controlled trials[J]. Diabetes Metab,2020.[Online ahead of print]

[11] YAN J,YAO B,KUANG H,et al. Liraglutide,sitagliptin,and insulin glargine added to metformin:The effect on body weight and intrahepatic lipid in patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease[J]. Hepatology,2019,69(6):2414-2426.

[12] TIAN F,ZHENG Z,ZHANG D,et al. Efficacy of liraglutide in treating type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease[J]. Biosci Rep,2018,38(6):BSR20181304.

[13] SMITS MM,TONNEIJCK L,MUSKIET MH,et al. Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes:A randomised placebo-controlled trial[J]. Diabetologia,2016,59(12):2588-2593.

[14] SMITH BW,ADAMS LA. Nonalcoholic fatty liver disease and diabetes mellitus:Pathogenesis and treatment[J]. Nat Rev Endocrinol,2011,7(8):456-465.

[15] QIU H,YANG JK,CHEN C. Influence of insulin on growth hormone secretion,level and growth hormone signalling[J]. Acta Physiol Sin,2017,69(5):541-556.(in Chinese)邱涵，杨金奎，陈晨．胰岛素对生长激素的分泌和细胞内信号传导的影响[J]．生理学报，2017,69(5):541-556.

[16] SHI ZP,YANG Y,LEI Y,et al. Liraglutide ameliorates hepatic expression of c-Jun N-terminal protein kinase in type 2 diabetic rats with nonalcoholic fatty liver diseas[J]. Chin J Diabetes,2016,8(9):548-553.(in Chinese)石志平，杨昱，雷营，等．利拉鲁肽降低2型糖尿病伴非酒精性脂肪性肝病大鼠肝脏磷酸化c-Jun氨基末端激酶的蛋白表达[J]．中华糖尿病杂志，2016,8(9):548-553.

[17] SZEGEZDI E,LOGUE SE,GORMAN AM,et al. Mediators of endoplasmic reticulum stress-induced apoptosis[J]. EMBO Rep,2006,7(9):880-885.

[18] KIM I,XU W,REED JC. Cell death and endoplasmic reticulum stress:Disease relevance and therapeutic opportunities[J].Nat Rev Drug Discov,2008,7(12):1013-1030.

[19] ZHAO L,ACKERMAN SL. Endoplasmic reticulum stress in health and disease[J]. Curr Opin Cell Biol,2006,18(4):444-452.

[20] XU K,WANG X,SHI Q,et al. Human prion protein mutants with deleted and inserted octarepeats undergo different pathways to trigger cell apoptosis[J]. J Mol Neurosci,2011,43(3):225-234.

[21] LAMPROPOULOU E,LYMPEROPOULOU A,CHARONIS A.Reduced expression of ERp46 under diabetic conditions inβ-cells and the effect of liraglutide[J]. Metabolism,2016,65(1):7-15.

[22] AO N,YANG J,WANG X,et al. Glucagon-like peptide-1preserves non-alcoholic fatty liver disease through inhibition of the endoplasmic reticulum stress-associated pathway[J].Hepatol Res,2016,46(4):343-353.

[23] KAZANKOV K,JRGENSEN S,THOMSEN KL,et al. The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis[J]. Nat Rev Gastroenterol Hepatol,2019,16(3):145-159.

[24] LUO W,XU Q,WANG Q,et al. Effect of modulation of PPAR-γactivity on Kupffer cells M1/M2 polarization in the development of non-alcoholic fatty liver disease[J]. Sci Rep,2017,7:44612.

[25] SOHN W,JUN DW,LEE KN,et al. Lactobacillus paracasei Induces M2-dominant Kupffer cell polarization in a mouse model of nonalcoholic steatohepatitis[J]. Dig Dis Sci,2015,60(11):3340-3350.

[26] LECLERCQ IA,FARRELL GC,SEMPOUX C,et al. Curcumin inhibits NF-kappaB activation and reduces the severity of experimental steatohepatitis in mice[J]. J Hepatol,2004,41(6):926-934.

[27] YU J,IP E,DELA PEA A,et al. COX-2 induction in mice with experimental nutritional steatohepatitis:Role as pro-inflammatory mediator[J]. Hepatology,2006,43(4):826-836.

[28] LUO Y,YANG P,LI Z,et al. Liraglutide improves non-alcoholic fatty liver disease in diabetic mice by modulating inflammatory signaling pathways[J]. Drug Des Devel Ther,2019,13:4065-4074.

[29] ZHOU JY,POUDEL A,WELCHKO R,et al. Liraglutide improves insulin sensitivity in high fat diet induced diabetic mice through multiple pathways[J]. Eur J Pharmacol,2019,861:172594.

[30] GUO S. Insulin signaling,resistance,and the metabolic syndrome:Insights from mouse models into disease mechanisms[J]. J Endocrinol,2014,220(2):T1-T23.

[31] BOUCHER J,KLEINRIDDERS A,KAHN CR. Insulin receptor signaling in normal and insulin-resistant states[J]. Cold Spring Harb Perspect Biol,2014,6(1):a009191.

[32] RONCERO I,ALVAREZ E,ACOSTA C,et al. Insulin-receptor substrate-2(irs-2)is required for maintaining glucokinase and glucokinase regulatory protein expression in mouse liver[J]. PLo S One,2013,8(4):e58797.

[33] YONEYAMA Y,LANZERSTORFER P,NIWA H,et al. IRS-1acts as an endocytic regulator of IGF-I receptor to facilitate sustained IGF signaling[J]. Elife,2018,7:e32893.

[34] KUBOTA N,TOBE K,TERAUCHI Y,et al. Disruption of insulin receptor substrate 2 causes type 2 diabetes because of liver insulin resistance and lack of compensatory beta-cell hyperplasia[J]. Diabetes,2000,49(11):1880-1889.

[35] YANG P,LIANG Y,LUO Y,et al. Liraglutide ameliorates nonalcoholic fatty liver disease in diabetic mice via the IRS2/PI3K/Akt signaling pathway[J]. Diabetes Metab Syndr Obes,2019,12:1013-1021.

[36] POLYZOS SA,KOUNTOURAS J,ZAVOS C,et al. The role of adiponectin in the pathogenesis and treatment of non-alcoholic fatty liver disease[J]. Diabetes Obes Metab,2010,12(5):365-383.

[37] HSIEH CJ,WANG PW,HU TH. Association of adiponectin gene polymorphism with nonalcoholic fatty liver disease in Taiwanese patients with type 2 diabetes[J]. PLo S One,2015,10(6):e0127521.

[38] FINKEL T,DENG CX,MOSTOSLAVSKY R. Recent progress in the biology and physiology of sirtuins[J]. Nature,2009,460(7255):587-591.

[39] XU F,LI Z,ZHENG X,et al. SIRT1 mediates the effect of GLP-1 receptor agonist exenatide on ameliorating hepatic steatosis[J]. Diabetes,2014,63(11):3637-3646.

[40] DENG XQ,CHEN LL,LI NX. The expression of SIRT1 in nonalcoholic fatty liver disease induced by high-fat diet in rats[J]. Liver Int,2007,27(5):708-715.

[41] PFLUGER PT,HERRANZ D,VELASCO-MIGUEL S,et al.Sirt1 protects against high-fat diet-induced metabolic damage[J]. Proc Natl Acad Sci U S A,2008,105(28):9793-9798.

[42] RODGERS JT,PUIGSERVER P. Fasting-dependent glucose and lipid metabolic response through hepatic sirtuin 1[J].Proc Natl Acad Sci U S A,2007,104(31):12861-12866.

施引文献

资源附件(0)

访问统计